




RealRate

# PHARMACEUTICAL 2023

Histogen Inc.  
Rank 213 of 446





RealRate

# PHARMACEUTICAL 2023

Histogen Inc.  
Rank 213 of 446



The relative strengths and weaknesses of Histogen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Histogen Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of Histogen Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 100%, being 57% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,456
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,234
Liabilities, Non-Current	4,379
Other Assets	5,181
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	84
Other Net Income	-1.0
Other Revenues	3,769
Property and Equipment	436
Research and Development	5,021
Selling, General and Administrative Expense	9,391

Output Variable	Value in 1000 USD
Assets	19,073
Liabilities	5,697
Expenses	14,412
Revenues	3,769
Stockholders Equity	13,376
Net Income	-10,644
Comprehensive Net Income	-10,644
Economic Capital Ratio	100%